Онкология. Журнал им. Па. Герцена, 6, 2017
 Скачать 194.41 Kb.
|
|
Выписка препарата на рецептурном бланке. При выписывании препарата следует указать его составляющие по МНН. Rp: Oxycodoni 0,02 Naloxoni 0,01 Dtd № 20 (двадцать) in tabl S: по 1 табл. 2 раза в сутки Oxycodoni 20 mg Naloxoni 10 mg Dtd № 20 (двадцать) in tabl S: по 1 табл. 2 раза в сутки Препарат следует выписывать на специальном рецептурном бланке формы №107/у-НП, для выписки наркотических препаратов. Возможно, что уже в ближайшие месяцы мы сможем его выписывать, по тем же правилам, как и ТТС фентанила — на рецептурном бланке формы у, ул, у (л). Поскольку ограничений по предельно допустимому количеству на один рецептурный бланк законодательством не введено, следует руководствоваться здравым смыслом и выписывать препарат на начальном этапе на 5—10 дней, при подобранной дозе до 15—20 дней терапии, поскольку пациент, который получает сильнодействующие лекарства, должен регулярно наблюдаться у врача с целью мониторинга его состояния. Заключение Появление в нашей практике новых препаратов опи- оидного ряда, защищенных полностью или частично от использования в немедицинских целях, позволит нам облегчать страдания и улучшать качество жизни паллиативных пациентов и их близких. Полноценный контроль боли — это фундаментальное право человека, а рациональное применение лекарственных средств — один из важнейших способов реализации этого права. Авторы заявляют об отсутствии конфликта интересов. ЛИТЕРАТУРА /REFERENCES 1. Davis MP. Opioids for cancer pain. (2 ed.). Oxford UK: Oxford University Press; 2009. https://doi.org/10.1093/med/9780199236640.001.0001 2. Инструкция к препарату морфина сульфат на официальном сайте Государственный реестр лекарственных средств. Ссылка активна на 08.07.2017. (In Russ.)]. http://grls.rosminzdrav.ru/ [The instruction to the drug morphine sulfate on the official website of the State register of medicines 3. Caraceni A, Hanks G, Kaassa S, Bennett MI, Brunelli С, Cherny N et al. Use of Opioid Analgesics in the Treatment of Cancer Pain: Evidence-based Recommendations from the EAPC. Lancet Oncol . 2012;13:e58-e68. http://www.eapcnet.eu https://doi.org/10.1016/s1470-2045(12)70040-2 4. National Institute for Health and Clinical Effectiveness (NICE). Guide to the Methods of Technology Appraisal [reference N0515] (2004). http://www.dft.gov.uk/dvla/medical/ataglance.aspx ОНКОЛОГИЯ. ЖУРНАЛ им. ПА. ГЕРЦЕНА, 6, 2017 70 5. Swarm Robert A, Anghelescu DL et al. National comprehensive cancer network (NCCN) Guidelines Version 1.2017 Panel Mem- bers Adult Cancer Pain Clinical practice Guidelines in oncology, 2017. Ссылка активна на 08.07.2017. https://utah.pure.elsevier. com/en/publications/adult-cancer-pain-clinical-practice- guidelines-in-oncology 6. Twycross R, Wilcock A, Howard P. PCF5+, Palliative Care For- mulary September 2015. includes monographs and: www.pallia- tivedrugs.com. https://doi.org/10.1177/0269216312450126 7. World Health Organization: Cancer pain relief: with a guide to opioid availability. 2nd edition. Geneva; 1996. http://www.who.int/cancer/palliative/painladder/en 8. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Faniz- za C et al. Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. Journal of clinical oncolo gy. 2015. December 7. https://doi.org/10.1200/jco.2015.61.0733 9. Dean L. Tramadol Therapy and CYP2D6 Genotype. Medical Ge- netics Summaries. September 10, 2015. https://www.ncbi.nlm.nih.gov/books/NBK315950/ 10. Care Quality Commission and NHS England (2013) Safer use of controlled drugs — preventing harms from fentanyl and buprenor- phine transdermal patches. Use of controlled drugs supporting information. www.cqc.org.uk https://doi.org/10.1007/s40278-016-16664-2 11. Fentanyl transdermal patch and fatal adverse reactions. Health. Canada. Canadian Adverse Reaction Newsletter. 2008;18(3):1-2. https://doi.org/10.2165/00128415-200811840-00003 12. FDA.2007. Fentanyl transdermal system (marketed as Duragesic) Information. Post market drug safety information for patients and providers. www.fda.gov/Drugs/DrugSafety. https://doi.org/10.2165/00128413-200715780-00059 13. MHRA. 2008. Fentanyl patches: serious and fatal overdose from dosing errors, accidental exposure, and inappropriate use. Drug Safety Update. 2. www.mhra.gov.uk/safetyinformation 14. Инструкция к препарату ТТС фентанила на официальном сайте Государственный реестр лекарственных средств. Ссылка активна на 08.07.2017. [The instruction to TTS fen- tanyl on the official website of the State register of medicines. (In Russ.)]. http://grls.rosminzdrav.ru 15. Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombe- si P et al. Adverse effects of transdermal opiates treating moder- ate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. Journal of Palliative Medicine. 2008;11:492-501. https://doi.org/10.1089/jpm.2007.0200 16. Hannon B, Zimmermann C, Bryson JR. The role of fentanyl in refractory opioid-related acute colonic pseudo-obstruction. Jour- nal of Pain and Symptom Management. 2013;45:e1-3. https://doi.org/10.1016/j.jpainsymman.2012.11.002 17. Koo HC, Moon JH, Choi HJ, Hwang KH, Maeng HJ, Kim HK et al. Effect of transdermal fentanyl patches on the motility of the sphincter of oddi. Gut and Liver. 2010;4:368-372. https://doi.org/10.5009/gnl.2010.4.3.368 18. Nomura M, Inoue K, Matsushita S, Takahari D, Kondoh C, Shi- tara K, et al. Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain. Clin J Pain. 2013;29(6):487-491. https://doi.org/10.1097/ajp.0b013e318266f6a5 19. Marquardt KA, Tharratt RS, Musallaml NA. Fentanyl remaining in a transdermal system following three days of continuous use. Annals of Pharmacotherpy . 1995;29:969-971. https://doi.org/10.1177/106002809502901001 20. Tarja Heiskanen, Sorjo Mätzke, Soile Haakana, Merja Gergov, Erkki Vuori, Eija Kalso. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144:218-222. https://doi.org/10.1016/j.pain.2009.04.012 21. Jonathan Hadgraft, Majella E Lane. Skin permeation: the years of enlightenment. International Journal of Pharmaceutics. 2005;305(1-2):2-12. https://doi.org/10.1016/j.ijphar.2005.07.014 22. Wolfgang Korte, Noémi de Stoutz, Rudolf Morant. Day-to-day ti- tration to initiate transdermal fentanyl in patients with cancer pain: short and long term experiences in a prospective study of 39 patients. Journal of Pain and Symptom Management . 1996;11(3):139-146. https://doi.org/10.1016/0885-3924(95)00162-x 23. Клинические рекомендации Хронический болевой синдром (ХБС) у взрослых пациентов, нуждающихся в паллиативной медицинской помощи, 2016, Минздрав РФ, Москва, 59 с. Ссылка активна на 08.07.2017. [Clinical guidelines: chronic pain syndrome in adult patients requiring palliative care. 2016. Minzdrav RF, Moscow, 59 p. (In Russ.)]. http://cr.rosminzdrav.ru/schema 24. Ans PE Vielvoye-Kerkmeer, Carlien Mattern, Martin P Uitendaal. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. Journal of Pain and Symptom Management. 2000;19(3):185-192. https://doi.org/10.1016/s0885-3924(99)00152-9 25. Mohamed Omar Tawfik, Vladimir Bryuzgin, Galina Kourteva. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Current Medical Research Opinion. 2004;20(3):259-267. https://doi.org/10.1185/030079903125003026 26. Абузарова ГР. Диагностика и дифференцированная фармакотерапия хронического болевого синдрома у онкологических больных. М.: ГЭОТАР-Медиа; 2015. [Abuzarova GR. Diagnostika I differ- encirovannaya farmacoterepiya khronicheskogo bolevogo sindroma u oncologicheskih bolnyh. M.: GEOTAR-Media; 2015. (In Russ.)]. 27. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinet- ics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. British Journal of Clinical Phar- macology. 1992;33(6):617-621. https://doi.org/10.1111/j.1365-2125.1992.tb04090.x 28. Fraser B Ross, Steven C Wallis, Maree T Smith. Co-administra- tion of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side- effects in rats. Pain. 2000;84(2):421-428. https://doi.org/10.1016/s0304-3959(99)00230-4 29. Lynn Webster. Efficacy and safety of dual-opioid therapy in acute pain. Pain Medicine. 2012;13(Suppl.1):12-20. https://doi.org/10.1111/j.1526-4637.2012.01330.x 30. Patricia Richards, Dennis Riff, Robin Kelen, Warren Stern. An- algesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo) in the treatment of postoperative pain. Journal of Opioid Management. 2011;7(3):217-228. https://doi.org/10.5055/jom.2011.0064 31. Felix A de la Iglesia, Gary W Pace, Gary LWG Robinson, Nuo-Yu Huang, Warren Stern, Patricia Richards. Tolerability and efficacy of two synergistic ratios of oral morphine and oxycodone combi- nations versus morphine in patients with chronic noncancer pain. Journal of Opioid Management . 2012;8(2):89-98. https://doi.org/10.5055/jom.2012.0101 32. Suzuki M, Sakurada T, Gotoh K, Watanabe S, Satoh N. Correla- tion between the administration of morphine or oxycodone and the development of infections in patients with cancer pain. Ameri- can Journal of Hospice and Palliative Care. 2012;30(7):712-716. https://doi.org/10.1177/1049909112469823 33. Tarja Heiskanen, Klaus T Olkkola, Eija Kalso. Effects of blocking CYP2D6 on oxycodone. Clinical Pharmacology and Therapeutics. 1998;64:603-611. https://doi.org/10.1016/s0009-9236(98)90051-0 34. Lalovic B, Kharash E, Hoffer C, Risler L,Liuchen L, Shen D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical Pharmacology and Therapeutics. 2006;79(5):461-479. ОБЗОРЫ ЛИТЕРАТУРЫ ОНКОЛОГИЯ. ЖУРНАЛ им. ПА. ГЕРЦЕНА, 6, 2017 71 35. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Har- sanyi Z, Babul N, Ford I. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxy- codone with controlled-release morphine in patients with cancer pain. Journal of Clinical Oncology. 1998;16(10):3222-3229. https://doi.org/10.1200/jco.1998.16.10.3222 36. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained- release morphine with sustained-release oxycodone in advanced cancer patients. British Journal of Cancer. 2003;89(11):2027-2030. https://doi.org/10.1038/sj.bjc.6601365 37. Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, Sevcik P, Hakl M, Hrib R, Uhl R, Dürr H, Reimer K. Long-term efficacy and safety of combined prolonged-release oxy- codone and naloxone in the management of non-cancer chronic pain. International Journal of Clinical Practice. 2010;64(6):763- 774. https://doi.org/10.1111/j.1742-1241.2010.02360.x 38. Инструкция к препарату таргин (налоксон/оксикодон). [The instruction to the drug targin (oxycodone+naloxone) on the of- ficial website. Ссылка активна на 08.07.2017. (In Russ.)]. http://grls.rosminzdrav.ru 39. Johannes Oppermann, Jan Bredow, Christian K Spies, Julia Lem- ken, Frank Unglaub, Christoph K Boese, Jens Dargel, Peer Eysel, Jan Zöllner. Effect of prolonged-released oxycodone/naloxone in postoperative pain management after total knee replacement: a nonrandomized prospective trial. Journal of Clinical Anesthesia. 2016;33:491-497. https://doi.org/10.1016/j.jclinane.2016.04.002 40. Kuusniemi K, Zöllner J, Sjövall S, Huhtala J, Karjalainen P, Kokki M, Lemken J, Oppermann J, Kokki H. Prolonged-release Oxycodone/Naloxone in Postoperative Pain Management: From a Randomized Clinical Trial to Usual Clinical Practice. Journal of International Medical Research. 2012;40(5):1775-1793. Поступила 19.06.2017 |